1Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J - αastroenterol, 1999,34( 1 ): 66 ～ 64.
2H C Reinecklr, M Steffen, T Witthoeft, et al. Enhanced secretion of tumour necrosis factor- alpha IL- α and IL- 8β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn' s disease. Clin Exp Immunol, 1993,94:174 ～181.
3Beil W J, Weller P F,PeppercomM A,et al. Ultrastructural immunogold localization of subcellular sites of TNF - αlpha in colonic Crohn' s disease. J - Leukoc - Biol, 1995,58(3) :284 ～ 298.
4F Casellas, M Papo, F Guarner, et al. Intraluminal colonic release of imunoreactive tumour necrosis factor in chronic ulcerative colitis. Clinical Science, 1994 (87) :453 ～458.
5J F Mouser, PharmD, J S Hyams. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's Disease Clinical Therapeutics, 1999,21(6) :932 ～ 942.
6Hanauer SB, Sandbom WJ, Katz S, et al. Etanercept for active Crohn' s disease: Gastroenterology, 2001,120(5): 1088 ～ 1094.
7Targan SR, Hanauer SB, van Deventer SJ,et al.A shor- αerm study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn' s Disease. Crohn' s disease cA2 study group. N Engl δMed , 1997,337:1029～ 1035.
8Kaser A, Mairinger T, Vogel W, et al. Infliximab in severe steroid - refractory ulcerative colitis: a pilot study. Wien - Klin - Wochenschr. ,2001,113(23 ～ 244) :930 ～ 933.
9Sands B E, Tremaine W J, Sandborn W J, et al. Infliximab in the treatment of severe,steroid-refractory ulcerative colitis: a pilot study. Inflamm- Bowel- Dis,2001,7(2): 83～88.
10R J Farrell. Intravenous hydrocortisone premedication prevents antibodies to infliximab in Crohn' s Disease. Gastroenterology, 2003,124 ( 4 ): 874
